ClinicalTrials.govpublic full text
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
relapsed/refractory al amyloidosis, azd0120, gc012f, amyloidosis, al amyloidosis, car-t, cell therapy, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 805704
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.